- Treatment with degludec may result in greater glycemic control and a lower risk of severe hypoglycemic events vs glargine in patients with type 2 diabetes (T2D).
Why this matters
- Patients with T2D are at risk of poorly controlled disease and hypoglycemic events.
- Patients with T2D were randomly assigned:
- Once-daily degludec U200 with or without oral antidiabetic drugs (n=805);
- Once-daily glargine U300 with or without oral antidiabetic drugs (n=804).
- The primary endpoint included the number of severe or blood glucose-confirmed symptomatic hypoglycemic events during the 36-week maintenance period.
- Funding: Novo Nordisk.
- No difference was observed between the degludec and glargine groups for the primary endpoint (risk ratio [RR], 0.88; 95% CI, 0.73-1.06; P=.17).
- The risk of nocturnal symptomatic events was lower in the degludec arm vs the glargine group (RR, 0.63; 95% CI, 0.48-0.84; P=.0014).
- Treatment with degludec was associated with fewer severe hypoglycemic events requiring third-party assistance (RR, 0.20; 95% CI, 0.07-0.57; P=.0027).
- Fasting plasma glucose was lower in the degludec arm at 88 weeks (5.9 vs 6.5 mmol/L; estimated treatment difference, −0.62 mmol/L; 95% CI, −0.82 to −0.43; P<.0001>
- Relatively short follow-up period.